4.5 Article

NCCN Guidelines® Insights Hepatobiliary Cancers, Version 1.2017 Featured Updates to the NCCN Guidelines

Journal

Publisher

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2017.0059

Keywords

-

Categories

Funding

  1. Astellas
  2. AstraZeneca
  3. Celldex Therapeutics
  4. Clovis Oncology
  5. Genomic Health, Inc.
  6. Kyowa Hakko Kirin
  7. Jazz Pharmaceuticals
  8. Novartis Pharmaceuticals Corporation
  9. NOVOCURE
  10. Merck Co., Inc.

Ask authors/readers for more resources

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available